Clinical Trial Update: Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia [Phase 3]

View source ↗

Summary

Phase 3 global safety and efficacy trial of crinecerfont for congenital adrenal hyperplasia has posted results; the study is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Adrenal Hyperplasia

Drugs mentioned

• Crinecerfont (crinecerfont)

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Congenital Adrenal Hyperplasia | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-02-05